Abstract |
A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985. In 1987, his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with 131I-metaiodobenzylguanidine ( MIBG) showed multiple bone and liver metastases. He was treated twice with infusions of 3.7 GBq of 131I-MIBG. After the first treatment, he had transient hypertension and pain in the back and right leg. Subsequent 131I-MIBG scintigraphy showed that the number of metastatic tumors had decreased. The second treatment was less effective. Excess catecholamines were treated with alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor, at doses between 250 and 2000 mg/day, which significantly decreased urinary NE excretion. This is the first case treated with 131I-MIBG in Japan.
|
Authors | Y Nakagami, K Nomura, K Kusakabe, N Miko, T Tsushima, H Demura |
Journal | Japanese journal of medicine
(Jpn J Med)
1990 May-Jun
Vol. 29
Issue 3
Pg. 329-33
ISSN: 0021-5120 [Print] Japan |
PMID | 1980321
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Iodine Radioisotopes
- Iodobenzenes
- Methyltyrosines
- Normetanephrine
- 3-Iodobenzylguanidine
- Metanephrine
- Vanilmandelic Acid
- alpha-Methyltyrosine
- Tyrosine 3-Monooxygenase
- Norepinephrine
- Epinephrine
|
Topics |
- 3-Iodobenzylguanidine
- Adrenal Gland Neoplasms
(diagnosis, drug therapy, metabolism)
- Antineoplastic Agents
(therapeutic use)
- Blood Chemical Analysis
- Epinephrine
(metabolism)
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Iodobenzenes
(therapeutic use)
- Male
- Metanephrine
(metabolism)
- Methyltyrosines
(therapeutic use)
- Middle Aged
- Norepinephrine
(metabolism)
- Normetanephrine
(metabolism)
- Pheochromocytoma
(diagnosis, drug therapy, metabolism)
- Radionuclide Imaging
- Tyrosine 3-Monooxygenase
(administration & dosage)
- Vanilmandelic Acid
(metabolism)
- alpha-Methyltyrosine
|